Company profile

Solventum Corp

NYSE:SOLVMedical/Dental Instruments

Drug pipeline (4)

AssetStageRevenueTrialsStatus
Alcoholapproved1approved
Chlorhexidine Gluconateapproved7approved
IODINE POVACRYLEXapproved0
Isopropyl alcoholapproved0

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (16)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT04601103terminated2020-01-062020-03-10Solventum US LLC3M Oral Rinse Incidence and Patient Acceptance of Sloughing When Used With Sodium Lauryl Sulfate (SLS) Toothpastes
NCT00731042phase4completed2008-03-012008-04-01Solventum US LLCA Two-week Crossover Evaluation of Two Hand Antiseptic Products on Skin Condition in Healthy Human Subjects
NCT00516906phase2_3completed2007-10-012007-12-01Solventum US LLCClinical Performance of a Chlorhexidine Antimicrobial Dressing
NCT01290978phase4completed2010-02-012010-03-01Solventum US LLCCompare Effect of Surgical Antiseptic Preparations on Incise Drape Adhesion to Skin
NCT03155204completed2017-04-252018-01-21Solventum US LLCComparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With A Reference Product

FDA applications (4)

ApplicationTypeApplicantProducts
NDA 019028NDASOLVENTUM US LLC
NDA 021074NDASOLVENTUM US LLC
NDA 021586NDASOLVENTUM US LLC
NDA 208288NDASOLVENTUM US LLC